Antiverse, a biotechnology company based in Cardiff, has announced the closing of a $9.3 million Series A funding round.

Funding Goals

The company will use the funds to expand its AI-powered computational platform, focused on therapeutic antibody discovery. The goal is also to accelerate lead programmes toward the in vivo studies phase.

Investors

The round was led by Soulmates Ventures, with participation from Innovation Investment Capital, DOMiNO Ventures, and existing backers including DBW and Kadmos Capital.

Background

Drug discovery through artificial intelligence is becoming an increasingly relevant field. AI can accelerate the identification of potential drug candidates, reducing research and development times and costs. This approach is particularly useful in developing personalized therapies and combating complex diseases.